Previous Article | Next Article ![]()
Infection and Immunity, July 2003, p. 3914-3919, Vol. 71, No. 7
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.7.3914-3919.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, Sackler Institute,1 Department of Medicine, New York University School of Medicine,2 Department of Veterans Affairs Medical Center, New York, New York3
Received 10 February 2003/ Returned for modification 17 March 2003/ Accepted 15 April 2003
|
|
|---|
cells, restored AI-2 activity to these cells. To evaluate whether BA5047 is essential for AI-2 synthesis, it was deleted through allelic exchange with marker rescue; the resulting mutant had no functional luxS activity and had reduced growth in vitro. In the wild-type strain, AI-2 activity was greatest during the exponential phase of growth. In total, these data indicate that BA5047 is a functional luxS ortholog in B. anthracis necessary for growth-phase-specific AI-2 expression. Thus, B. anthracis may utilize extracellular signaling molecules to regulate density-dependent gene expression. |
|
|---|
Quorum sensing has been well characterized in Vibrio harveyi, a bioluminescent bacterium that freely lives in the ocean floor sediment or on the exterior of fish (17). The luminescence genes are expressed only when the V. harveyi populations are at high cell density under the control of the lux quorum-sensing system (13). The luxCDABE operon is regulated by two-component systems that are stimulated by the AI ligands, AI-1 (acyl-homoserine lactone [AHL]) and AI-2 (13). Synthesis of AI-1 requires luxLM. AI-1 diffuses freely through the cell wall into the extracellular milieu, and when sufficient quantities are recognized by its sensor histidine kinase, luxN, a hybrid two-component system-signaling cascade is initiated (13). The lux cascade also is regulated by another AI molecule, AI-2, which is predicted to be a furanosyl borate diester and is synthesized by the product of luxS (2). The luxS product converts S-ribosylhomocysteine to 4,5-dihydroxyl-2,3-pentanedione, catalyzing AI-2 formation (2). V. harveyi strain BB170, in which luxN is mutated, is unable to detect AI-1 molecules and may be used to detect AI-2 or AI-2-like molecules in its milieu (1).
Bacillus anthracis, a gram-positive, nonmotile, spore-forming bacterium, is the etiological agent of anthrax (15). Spores from B. anthracis are extremely resistant to a wide range of adverse environmental conditions, such as heat, UV and ionizing radiation, and chemical agents (15). With the emergence of B. anthracis spores as a weapon of terrorism (11), it is essential to develop new vaccines to prevent and new therapies to control B. anthracis infections. In the present report we demonstrate that B. anthracis possesses a luxS ortholog and synthesizes a functional AI-2 molecule and that a luxS mutant has slowed growth compared to that of a wild-type strain. These observations suggest modalities for both prevention and treatment of anthrax.
|
|
|---|
was routinely grown in Luria-Bertani broth at 37°C. Ampicillin (50 µg/ml) was added for cultivation of DH5
strains harboring recombinant plasmids. V. harveyi strain BB170, kindly provided by Bonnie Bassler (Princeton University, Princeton, N.J.), was routinely grown in Auto-Inducer Bioassay medium (AB) (22) at 30°C. |
View this table: [in a new window] |
TABLE 1. Plasmids and strains used in this study
|
Construction of B. anthracis
luxS strain.
To construct a luxS mutant, 1.18-kb and 989-bp fragments flanking BA5047 were amplified by using oligonucleotides BAluxSKOF1 (5'-GACTCAGTAACAGAACGTCGG-3'), BAluxSKOR1 (5'-CGCAATCTCTTACATAAGGTG-3'), BAluxSKOF2 (5'-CACATGTGGTCAAGCGAAG-3'), and BAluxSKOR2 (5'-GCCACATCATATCCAGTATTCG-3'). The PCR-amplified products were purified by using a Qiagen PCR purification kit and subsequently were digested with HindIII. Digest fragments were cloned into pGEM-T Easy and were screened by PCR with primers BAluxSKOF1 and BAluxSKOR2; the plasmid with the correct insert is designated pMJ301. pMJ301 was digested with HindIII and aphA, conferring kanamycin resistance, and was introduced into pMJ301 to create pMJ301K (9). pMJ301K was digested with EcoRI, releasing the insert region, which was cloned into a pUC19 derivative (pUS19) with spectinomycin resistance to create pMJ301KS. Since methylation inhibits transformation into B. anthracis, pMJ301KS was cloned into dam-defective E. coli strain SCS110. Purified pMJ301KS from SCS110 was electroporated into B. anthracis strain 34F2, and colonies were selected for Kanr and Sper. Transformants were picked on medium containing 50 µg of kanamycin/ml and 100 µg of spectinomycin/ml and then were subcultured daily in the absence of antibiotics at 37° with aeration for 15 days. Individual colonies were subsequently screened to identify clones that were both Kanr and Spes. Clones with the correct antibiotic phenotype were confirmed by PCR to have allelic exchange of aphA in the luxS locus by using oligonucleotides SterneF (5'-GCAAATTGAAAACGACTCAG-3') and SterneR (5'-GTATGCTTATAAACATTCCGTCG-3'), with HindIII digestion of the PCR products.
Construction and screening for pMJ501.
Chromosomal DNA of B. anthracis strain 34F2 was purified by using the Wizard Genomic DNA Purification kit (Promega, Madison, Wis.) and was used as template for PCR amplification of open reading frame (ORF) BA5047. The oligonucleotides used were designated BAluxSF1 (5'-ATGCCATCAGTAGAAAGCTTTG-3') and BAluxSR2 (5'-CCAAATACTTTCTCAAGTTCATC-3'). In the PCR, DNA was denatured for 1 min at 94°C, with annealing for 1 min at 51°C and extension for 1 min at 72°C. The amplified product was cloned into pGEM-T Easy, yielding pMJ501, which then was transformed into E. coli strain DH5
with selection for ampicillin resistance. The insert from pMJ501 was subjected to sequence analysis by using vector primers T7F and SP6R to ensure that no nucleotide errors had been introduced in the cloning process. E. coli DH5
cells also were transformed with pGEM-T Easy alone for use as a control.
Genomic analysis. LuxS protein sequences were retrieved from the National Center for Biotechnology Information database, and alignments were created by using ClustalW (23). Phylograms based on amino acid alignments were generated by using Paup 4.0b8 (Sinauer Associates, Sunderland, Mass.) with generation of 1,000 replicate trees by using a full heuristic search (5).
Growth phase regulation of AI-2 synthesis in B. anthracis.
Overnight cultures of B. anthracis strain 34F2 were diluted to an optical density at 600 nm (OD600) of 0.03 in 50 ml of BHI and were grown at 37°C with aeration. Every 60 min, ODs of the cultures were measured by reading 1-ml aliquots with a Beckman DU7400 spectrophotometer. At sequential intervals, quantitative cultures were performed to determine bacterial CFU. From these same aliquots CFMs were prepared for use in the bioluminescence AI-2 reporter assay. All assays were repeated in triplicate. In separate experiments B. anthracis strains 34F2 and 34F2
luxS were grown overnight at 37°C with aeration. Cultures were used to inoculate fresh media to an OD600 of 0.03 and then were grown at 37°C with aeration. OD was measured over a 24-h period, since this may be more accurate than cell count due to chaining in B. anthracis cultures (16).
|
|
|---|
![]() View larger version (11K): [in a new window] |
FIG. 1. Schematic of B. anthracis chromosomal organization in the region of the putative luxS homolog. The B. subtilis nucleotide sequence was used to identify a putative luxS homolog in the B. anthracis genome. BLASTN analysis revealed an ORF (BA5047) in the partially annotated B. anthracis genome that was 72% identical to luxS in B. subtilis. Arrows indicate the direction of transcription. Black arrows indicate the locations of primers for construction of 34F2 luxS.
|
![]() View larger version (15K): [in a new window] |
FIG. 2. Phylogenetic analysis of translated products of luxS orthologs from 17 bacterial species and B. anthracis ORF BA5047. Sequences were aligned by using the GCG Pileup program and were subjected to phylogenetic analysis by using PAUP 4.0b4a. Bootstrap values of more than 50% (based on 1,000 replicates) are represented at each node, and the branch length index is represented below the phylogram. The genus and species for each sequence are located at the termination of each branch.
|
![]() View larger version (15K): [in a new window] |
FIG. 3. Induction of bioluminescence in V. harveyi reporter strain by CFM from B. anthracis cells. V. harveyi strain BB170 is deficient in the AI-1 sensor encoded by luxN, and thus upregulates only the expression of the lux operon (measured as RLU) when AI-2 or AI-2-like molecules are present in its milieu (1). CFM obtained from AI-2-synthesizing bacteria grown to high density (including BB170, in which the AI-2-regulated system is intact) can induce expression of the bioluminescence-generating luxCDABE operon in BB170. In the experiments shown, sterile CFM alone and CFM from high-density cultures of V. harveyi strain BB170 were negative and positive controls, respectively, and CFM from high-density 6-h cultures of B. anthracis strain 34F2 and 34F2 luxS were the unknowns. Cells of BB170 were grown for 2 h (black boxes) or 4 h (white boxes) in the presence of sterile CFM. The baseline is the value for use of uninoculated (sterile) CFM alone at 2 h. By 4 h the endogenous AI-2 activity was substantially higher than that at 2 h. Each bar represents the means (± standard deviations) of triplicate experiments. Compared to the negative control, wild-type 34F2 but not 34F2 luxS showed substantial AI-2 activity.
|
to synthesize a functional AI-2 molecule (6). The B. anthracis luxS ortholog (BA5047) was amplified by PCR and was cloned into the E. coli shuttle vector pGEM-T Easy to create pMJ501. Only the ORF was cloned into pGEM-T Easy, into a site downstream of the vector's isopropyl-ß-D-thiogalactopyranoside (IPTG)-inducible promoter. CFM from high-density cultures of DH5
containing vector pMJ501 were induced with IPTG and then were screened for the synthesis of AI-2, as measured in the V. harveyi bioluminescence assay (Fig. 4). As negative controls, the reporter strain BB170 was incubated with sterile CFM alone or with CFM from high-density IPTG-induced cell cultures of E. coli strain DH5
without vector or containing pGEM-T Easy with no insert. As positive controls, CFM was used from high-density cultures of strain BB170 and B. anthracis strain 34F2. As previously shown, when sterile CFM alone was used as the baseline for bioluminescence, CFM from high-density cultures of strain BB170 and B. anthracis 34F2 induced substantial bioluminescence (Fig. 4). As expected, no bioluminescence was induced by CFM from cultures of DH5
or from DH5
containing pGEM-T Easy without insert. In contrast, CFM from DH5
containing pMJ501 induced a high level of bioluminescence, greater than that induced by CFM from the positive controls. Compared to the control E. coli CFMs, there was nearly a 1,000-fold mean increase in induction of bioluminescence by pMJ501 (Fig. 4).
![]() View larger version (23K): [in a new window] |
FIG. 4. Induction of bioluminescence in the V. harveyi reporter strain by cloned BA5047 in E. coli. V. harveyi strain BB170 upregulates only the expression of bioluminescence when AI-2 or AI-2-like molecules are present in its milieu, as described in the legend to Fig. 3. In the experiments shown, negative controls were BB170 cells incubated for 2 h with sterile CFM alone and CFM from high-cell-density cultures of E. coli strain DH5 alone or containing pGEM-T Easy without insert. Positive controls used were CFM from high-density cultures of V. harveyi strain BB170 and B. anthracis strain 34F2 (6-h culture). The unknown specimen was CFM from DH5 containing pMJ501; all assays were run in triplicate. The dashed line indicates the endogenous RLU for the BB170 cells grown for 2 h in the presence of sterile CFM alone.
|
luxS has a defect in AI-2 activity.
To analyze the effect of AI-2 signaling in B. anthracis, we created a
luxS mutant in strain 34F2 by replacement of the luxS homolog with a kanamycin resistance cassette (see Materials and Methods). After electroporation of the wild-type strain with the mutated locus on pMJ301KS, kanamycin-resistant transformants were serially passed for 15 days in vitro to select for a double-crossover event. Screening of one such Kanr Spes transformant by PCR showed the expected products (Fig. 5), indicating the proper construction. Additionally, in lane 3 of Fig. 5, the
0.4-kb band corresponds to a fragment of luxS amplified from genomic DNA from the wild-type strain. To determine the effect of the mutation on AI-2 synthesis, we utilized the V. harveyi bioassay as described above (Fig. 3). Compared to the baseline level of AI-2 activity in reporter strain BB170, CFM from a high-density culture of 34F2
luxS had no additional AI-2 activity. The data collected provided evidence that luxS is necessary for AI-2 synthesis in B. anthracis strain 34F2 (Fig. 3).
![]() View larger version (122K): [in a new window] |
FIG. 5. PCR confirmation of the creation of B. anthracis 34F2 luxS. Primers flanking the regions of recombination were used to confirm the construction of 34F2 luxS. The PCR products were from chromosomal DNA from wild-type strain 34F2 (lane 1) and from a putative 34F2 luxS clone (lane 2). The size change is indicative of the insertion of aphA, which encodes kanamycin resistance (9). The purified PCR products shown in lanes 1 and 2 were digested with HindIII and are shown in lanes 3 (wild-type strain) and 4 (putative 34F2 luxS clone). The new 1.4-kb band in lane 4 confirmed the insertion of aphA in the luxS locus. The numbers to the right of the gel indicate molecular size in kilobase pairs.
|
luxS.
When cultured in liquid medium, B. anthracis 34F2
luxS exhibits noticeable growth defects compared to wild-type B. anthracis 34F2 (Fig. 6A). As determined by cell density, 34F2
luxS has a brief delay (approximately 30 to 60 min) in the transition between lag and early exponential phase compared to those for wild-type 34F2. Subsequently, exponential growths for the wild-type and mutant strains are parallel, but the mutant enters into stationary phase at a much lower cell density. Thus, under the conditions tested AI-2 function appears necessary for full B. anthracis growth in vitro.
![]() View larger version (25K): [in a new window] |
FIG. 6. Growth rate and AI-2 production of B. anthracis strains 34F2 and 34F2 luxS. (A) B. anthracis strains 34F2 and 34F2 luxS were grown overnight in BHI medium and were inoculated with fresh BHI medium at an adjusted OD600 of 0.03. Cells of 34F2 (diamonds) and 34F2 luxS (squares) were grown for 24 h, and the OD was measured at regular intervals. Filtered CFM from the growth of strain 34F2 depicted in panel A was examined at various time points to ascertain AI-2 levels by using the V. harveyi bioassay described in the legend to Fig. 4. CFM from strain 34F2 luxS was collected at 6 h. (B) All filtered CFM from the 34F2 and 34F2 luxS cultures shown in panel A were adjusted to reflect an OD600 of 0.6 to standardize the cell numbers. Negative and positive controls were sterile CFM and CFM from high-density cultures of 34F2 luxS and V. harveyi, respectively.
|
luxS were used as negative controls, and CFM from a high-density culture of V. harveyi strain BB170 was used as a positive control. Analysis of CFM collected from B. anthracis showed that AI-2 is maximally synthesized during the mid-exponential phase of growth and diminishes during stationary phase. CFM collected from a 6-h culture of the wild-type strain did not enhance the growth of 34F2 (data not shown). |
|
|---|
That CFM from strain 34F2 was able to stimulate luminescence in V. harveyi strain BB170 (Fig. 3) indicates that B. anthracis produces AI-2 or an AI-2-like molecule, likely similar in structure to AI-2 from V. harveyi (2). With this evidence we next focused on BA5047, the luxS ortholog. Expression of B. anthracis BA5047 in E. coli strain DH5
demonstrates its central role in synthesis of AI-2 or an AI-2-like molecule (Fig. 4) and suggests the capability of B. anthracis to conduct density-dependent gene expression. Isogenic deletion of luxS (Fig. 5) resulted in an inability of the B. anthracis mutant (34F2
luxS) to produce AI-2 or an AI-2-like molecule that could be detected in the V. harveyi bioassay (Fig. 3). Similarly, compared to the wild-type strain the mutant showed delay in the transition from lag to exponential growth phase and entered stationary phase early (Fig. 6A). In total, the
luxS culture grew more slowly and produced fewer cells compared to the wild type.
B. anthracis synthesis of AI-2 or an AI-2-like molecule mediated by luxS thus plays an important role in the regulation of growth. As such, targets of the hypothesized density-dependent gene expression must include genes regulating vegetative growth and cell cycle. If B. anthracis regulates gene expression by means of an AI molecule, as do other pathogens (14), cells might have the ability to suppress virulence gene expression until the total population reaches a threshold density. Suppression of virulence gene expression by quorum sensing could allow B. anthracis to evade immune detection until its population is at a density sufficiently high to overwhelm the host's innate and adaptive defenses. That AI-2 synthesis is maximal during exponential phase growth is consistent with this hypothesis.
This hypothesis suggests that a possible means of treating anthrax could be via inhibitors of AI-2 to downregulate density-dependent gene expression. Recent data has shown that a synthetic furanone, (5Z)-4-bromo-5-(bromethylene)-3-butyl-2(5H)-furanone, has the ability to inhibit AI-2-mediated quorum sensing in E. coli and V. harveyi (19) as well as swarming and biofilm formation by B. subtilis (20). Examination of this or similar molecules could permit ascertainment of the role of AI-2-mediated mechanisms in virulence gene expression of B. anthracis.
This work was supported in part by RO1 GM 63270 from the National Institutes of Health, by the Medical Research Service of The Department of Veterans Affairs, by the David and Lucile Packard Foundation, and by the Ellison Medical Foundation.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»